☆ 4.7 Meeting Abstract

Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

BLOOD (2016)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.645.645

Keywords

-

Categories

Hematology

Funding

  1. Bristol-Meyers Squibb
  2. Takeda
  3. Onyx/Amgen
  4. Amgen
  5. Novartis
  6. Celgene
  7. Karyopharm
  8. Janssen
  9. Prothena

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.